known as "VIP36," works by binding to the cannabinoid "CB1" receptors on nerve cells found in the body's central and peripheral nervous systems, much as natural cannabinoids do, and reduce pain ...

Researchers from Washington University School of Medicine and Stanford University have developed a compound that simulates a ...

Poisonings linked to synthetic and semisynthetic cannabinoids (man-made products designed to mimic cannabis) are increasing ...

Chemically modifying a synthetic cannabinoid could enable scientists to capitalize on the body’s natural pain-killing pathway without evoking drug tolerance or psychoactivity. Read the paper ...

Cannabis smoking could cause an 'overdose' of the natural cannabinoid signalling system responsible for regulating sperm structure, vigour and fertility. Dr Herbert Schuel and colleagues believe that ...

Discover how terpenes work synergistically with cannabinoids to enhance medicinal effects, offering therapeutic benefits beyond what CBD and THC provide alone.

MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce ...

Synthetic cannabinoids, a class of new psychoactive substances, bind to cannabinoid receptors CB1 and CB2 much more strongly than tetrahydrocannabinol (THC) and cannabidiol (CBD), raising public ...